Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway

Journal of Medical Economics

Volumn 18, Issue 8, 2015, Pages 573-585

  Huetson, Pernilla ^a   Palmer, James L ^a   Levorsen, Andrée ^b   Fournier, Marie ^c   Germe, Maeva ^c   McLeod, Euan ^a  

^a IQVIA   (United States)

^b Sanofi ^*  (Norway)

^c SANOFI   (France)

Author keywords

Cost effectiveness; Lixisenatide; Modeling; Norway; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LIXISENATIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; LIPID; PEPTIDE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; BOLUS INJECTION; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSIS RELATED GROUP; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH STATUS; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORWAY; PATIENT CARE; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; TIME; UNITED KINGDOM; AGED; AGONISTS; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRINKING BEHAVIOR; ECONOMICS; HYPOGLYCEMIA; MIDDLE AGED; PROSPECTIVE STUDY; QUALITY OF LIFE; SMOKING; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

AGED; ALCOHOL DRINKING; BLOOD PRESSURE; BODY MASS INDEX; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEALTH EXPENDITURES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; MIDDLE AGED; NORWAY; PEPTIDES; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SMOKING; SOCIOECONOMIC FACTORS;

EID: 84964394145     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1038271     Document Type: Article

References (55)

1. International Diabetes Federation. IDF Diabetes Atlas. IDF, 2013. Available at: www.idf.org/diabetesatlas [last accessed 17 March 2013]
2. Strom H, Selmer R, Birkeland KI, et al. No increase in new users of blood glucose-lowering drugs in Norway 2006-2011: a nationwide prescription database study. BMC Public Health 2014;14:520
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macro-vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
4. The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
5. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:293-301
6. Solli O, Jenssen T, Kristiansen IS. Diabetes: cost of illness in Norway. BMC Endocrine Disorders 2010;10:1-8
7. Health and consumers directorate-general. Estimates of cost of diabetes per year in the European Union and in other European countries. European Commission, 2011. Available at: http://ec.europa.eu/health/major-chronic--diseases/docs/idf-cost-2011.pdf [last accessed 17 March 2013]
8. Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-77
9. Dilla T, Valladares A, Nicolay C, et al. Healthcare costs associated with change in body mass index in patients with type 2 diabetes mellitus in Spain: the ECOBIM study. Appl Health Econ Health Policy 2012;10:417-30
10. Van NK, Globe D, Ng-Mak D, et al. The association between employee obesity and employer costs: evidence from a panel of U.S. employers. Am J Health Promot 2014;28:277-85
11. Davis WA, Bruce DG, Davis TM. Economic impact of moderate weight loss in patients with type 2 diabetes: the Fremantle Diabetes Study. Diabet Med 2011;28:1131-5
12. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005;14:217-30
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
14. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6
15. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
16. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013;36:2489-96
17. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-12
18. Charbonnel B, Bertolini M, Tinahones FJ, et al. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complications 2014;28:880-6
19. Christensen M, Miossec P, Larsen BD, et al. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. Expert Opin Drug Discov 2014;9:1223-51
20. McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE Diabetes Model. Value Health 2014;17:714-24
21. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(SUPPL. 1):5-26
22. Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(SUPPL. 1):S27-40
23. World Health Organization Regional Office for Europe. European Detailed Mortality Database. WHO, 2014. Available at: http://data.euro.who.int/dmdb/ [Last accessed 25 October 2012]
24. The Norwegian Renal Registry. Annual Report 2011. NRR, 2011. Available at: http://www.nephro.no/nnr/AARSM2011.pdf [last accessed 17 March 2013]
25. Jenssen TG, Tonstad S, Claudi T, et al. The gap between guidelines and practice in the treatment of type 2 diabetes a nationwide survey in Norway. Diabetes Res Clin Pract 2008;80:314-20
26. Socialstyrelsen. Diabetesvård Landstingens och kommunernas insatser (diabetes care and local government operations). 2012. http://www.social-styrelsen.se/publikationer2012/2012-1-2 [last accessed 17 March 2013]
27. Noklus. Norwegian Quality Improvement of Primary Health Care Laboratories. 2014. Available at: http://www.noklus.no/Diabetesregisterforvoksne/Diabetesregisterforvoksne.aspx [last accessed March 17 2013]
28. Sundling V, Gulbrandsen P, Jervell J, et al. Care of vision and ocular health in diabetic members of a national diabetes organization: a cross-sectional study. BMC Health Serv Res 2008;8:159
29. McMullin J, Brozek J, Jaeschke R, et al. Glycemic control in the ICU: a multicenter survey. Intensive Care Med 2004;30:798-803
30. Lyon KC. The case for evidence in wound care: investigating advanced treatment modalities in healing chronic diabetic lower extremity wounds. J Wound Ostomy Continence Nurs 2008;35:585-90
31. Jones LE, Doebbeling CC. Depression screening disparities among veterans with diabetes compared with the general veteran population. Diabetes Care 2007;30:2216-21
32. Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5
33. Fritsche A, Larbig M, Owens D, et al. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes - results of the GINGER study. Diabetes Obes Metab 2010;12:115-23
34. Ligthelm RJ, Gylvin T, DeLuzio T, et al. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study. Endocr Pract 2011;17:41-50
35. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007;29:2349-64
36. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
37. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 2003;6:9-17
38. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
39. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003
40. Helsedirektoratet. ISF. 2013. Available at: www.helsedirektoratet.no/ [last accessed March 17 2013]
41. Den Norske legeforeingen. Normaltariffen. Den norske legeforening. 2013. Available at: http://legeforeningen.no/ [last accessed March 17 2013]
42. Statistics Norway. 2014. Available at: http://www.ssb.no/en/ [last accessed March 17 2013]
43. Price database. Norwegian Medicines Agency. 2013. Available at: http://www.legemiddelverket.no/Blaa-resept-og-pris/pris-paa-legemidler/maksi-malpris/Sider/default.aspx [last accessed March 17 2013]
44. Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009;25:542-8
45. Beaudet A, Clegg JP, Lloyd A. PDB54 systematic literature review of utility values associated with type 2 diabetes-related complications. Value Health 2012;15:A503
46. Solli O, Stavern K, Kristiansen IS. Health-related quality of life in diabetes: the associations of complications with EQ-5D scores. Health Qual Life Outcomes 2010;8:1-8
47. Guidelines on how to conduct pharamacoeconomic analyses. Norwegian Medicines Agency. 2012. Available at: http://www.legemiddelverket.no/English/price-and-reimbursement/application-for-reimursement/Lists/PageAttachments/default/NO/Pharmacoeconomic%20guidelines%20-%20Norway.pdf [last accessed March 17 2013]
48. Eli Lilly and company. Exenatide Once-Weekly (Bydureon) for the Treatment of Type 2 Diabetes. NICE, 2011. Available at: http://www.nice.org.uk/guidance/ta248/documents/diabetes-type-2-exenatide-prolonged-release-appraisal-consultation-manufacturer-submission-from-eli-lilly2 [last accessed 17 March 2013]
49. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40
50. Ray JA, Boye KS, Yurgin NR, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609-22
51. Beaudet A, Palmer JL, Timlin L, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ 2011;14:357-66
52. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86
53. Meyers JL, Parasuraman S, Bell KF, et al. The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data. Arch Public Health 2014;72:1-12
54. Raccah D, Lin J, Wang E, et al. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. J Diabetes Complications 2014;28:40-4
55. Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 2014;17:157-73